Black Diamond Therapeutics (NASDAQ:BDTX) reported encouraging Phase 2 data for its drug candidate BDTX-1535 in the treatment ...

On Monday, Black Diamond Therapeutics Inc (BDTX) stock saw a modest uptick, ending the day at $4.35 which represents a slight increase of $0.12 or 2.84% from the prior close of $4.23. The stock opened ...

The 555.55 carat black diamond has belonged to its current owner for two decades but little is known about its history before that. A billion-year-old black diamond, believed to be the largest cut ...

Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 23.80% ...

Shares in Black Diamond Therapeutics rose after the company outlined positive initial data from Phase 2 trials of BDTX-1535, an oral cancer treatment. Shares were up 46% in premarket trading at $6.94.

Black Diamond Therapeutics, Inc. (BDTX) announced positive initial Phase 2 results for BDTX-1535 in patients with relapsed or ...

Black holes are points in space that are so dense they create deep gravity sinks. Beyond a certain region, not even light can escape the powerful tug of a black hole's gravity. And anything that v ...

Black Diamond Therapeutics (BDTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on ...

The 34-year-old slips on a gold signet-style ring in the 12th-floor showroom of Vale Jewelry in New York City’s diamond district. “I don’t want a symbol of our union to also be associated ...

Firstly, we'll want to... Simply Wall St. Black Diamond Group's (TSE:BDI) investors will be pleased with their enviable 432% return over the last five years We think all investors should try to buy ...